Arcus Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary

Arcus Biosciences

25/02/2025 22:41

Arcus Biosciences Inc RCUS.N reported a quarterly adjusted loss of $1.03​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.08.  The mean expectation of twelve analysts for the quarter was for a loss of $1.25 per share. Wall Street expected results to range from $-1.58 to -99 cents per share.

Revenue fell 16.1% to $26.00 million from a year ago; analysts expected $28.90 million.

Arcus Biosciences Inc's reported EPS for the quarter was a loss of $1.03​.

The company reported a quarterly loss of $94 million.

Arcus Biosciences Inc shares had fallen by 31.8% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts was unchanged in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Arcus Biosciences Inc is $31.00

This summary was machine generated from LSEG data February 25 at 10:41 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-1.25
-1.03
Beat
Sep. 30 2024
-1.06
-1.00
Beat
Jun. 30 2024
-1.10
-1.02
Beat
Mar. 31 2024
-0.95
-0.05
Beat